Monitor for any further C-suite departures or delays in clinical development timelines. The internal absorption of CMO duties suggests continuity, but the lack of a named replacement could signal organizational flux.
Price Chart
Executive Summary
Protara Therapeutics disclosed the resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D., effective June 26, 2026, to pursue other opportunities. His responsibilities will be absorbed by existing clinical leadership, including Carla Beckham, M.D. and Jacqueline Zummo, Ph.D. This is a routine officer departure with no immediate financial or operational impact.
Key Facts
- Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to explore other opportunities.
- Duties will be subsumed by Lead Medical Director Carla Beckham, M.D. under oversight of Chief R&D Officer Jacqueline Zummo, Ph.D.
- No replacement CMO has been named; no compensation or employment agreement details were disclosed.
Financial Impact
No financial impact disclosed.
Risk Factors
- Potential disruption to clinical development programs if the departing CMO was a key driver.
- Further executive departures could signal broader organizational instability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-073184 |
| Document: 0001213900-26-073184-index-headers.html | 0001213900-26-073184 |
| Document: 0001213900-26-073184-index.html | 0001213900-26-073184 |
| Document: 0001213900-26-073184.txt | 0001213900-26-073184 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Aug 11, 2026 7w ago | Press Release | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Jun 29, 2026 13w ago | 8-K | $3.82 $4.04 | ▲ +5.76% | ▲ +6.79% | $2.70 (−29.32%) |
May 26, 2026 18w ago | EFFECT | $4.80 $4.06 | ▲ +15.52% | ▲ +13.57% | $2.70 (+43.75%) |
May 15, 2026 20w ago | Press Release | $5.10 $3.94 | ▼ −22.75% | ▼ −24.86% | $2.70 (−47.06%) |
May 13, 2026 20w ago | 8-K | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
May 13, 2026 20w ago | Press Release | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
Apr 28, 2026 22w ago | DEFA14A | $5.17 $4.75 | ▼ −8.12% | ▼ −14.17% | $2.70 (−47.78%) |
Mar 10, 2026 29w ago | Press Release | $5.71 $5.22 | ▼ −8.58% | ▼ −8.43% | $2.70 (−52.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access